Taupō woman with cystic fibrosis competing in Ironman next month

A New Zealand woman with cystic fibrosis is redefining the boundaries of athletic achievement, fueled by access to a life-changing medication and a deeply personal connection to the Ironman community. Kirsty Parsons, an IT professional from Taupō, recently aimed to become the first New Zealand woman with cystic fibrosis to complete an Ironman event on March 7th.

The Impact of Trikafta

Parsons’ journey highlights the transformative effect of Trikafta, a medication that addresses the underlying cause of cystic fibrosis and makes the condition more manageable. Approximately 500 New Zealanders live with cystic fibrosis, a condition for which there is currently no cure. Before gaining access to Trikafta, Parsons described her health as rapidly declining. “I was in my early 20s, so there was lots of living I wanted to do,” she stated.

Did You Know? Trikafta became publicly funded by Pharmac in New Zealand for individuals aged 6 and up in April 2023, with provisional funding extended to children aged 2 to 5 as of April 1st.

Parsons initially accessed Trikafta through a drug trial with Vertex in 2018 while living in England. The impact was immediate and profound. “All of my symptoms kind of just dropped away within the week,” she explained, describing it as “like being picked up and put in a brand new shiny body where everything worked.” Continued access to the drug was secured upon her return to New Zealand in 2021.

A Full-Circle Moment

Competing in the Ironman – a 3.8km swim, 180km cycle, and 42.2km marathon run – represented more than just a personal challenge for Parsons. It was a “full-circle moment,” given Cystic Fibrosis New Zealand (CFNZ) was a charity sponsor of Ironman New Zealand when she was younger. As a teenager, she was mentored by athlete Patrick Bristowe, who she describes as her “Ironman buddy,” and ran alongside him at the finish line.

Expert Insight: The story of Kirsty Parsons illustrates the potential for individuals with chronic conditions to achieve ambitious goals when provided with effective medical interventions. Her participation in an Ironman event not only demonstrates personal resilience but also challenges perceptions of what is possible for those living with cystic fibrosis.

Parsons dedicated her Ironman campaign to fundraising for CFNZ, and was almost halfway to her initial goal of raising $10,000, considering increasing it to $20,000. She emphasized the importance of CFNZ’s advocacy in securing funding for Trikafta and the support it provides to individuals and families affected by cystic fibrosis.

Looking Ahead

While the article does not detail Parsons’ race results, her commitment to the Ironman serves as a powerful example for others. Her efforts will inspire further participation in endurance events among individuals with cystic fibrosis. Continued funding for Trikafta could lead to improved health outcomes and increased opportunities for those living with the condition. CFNZ’s executive lead, Simone Brown, noted that Parsons’ achievement “shines a bright light on the potential life and future that our younger generations can look forward to and be inspired by.”

Frequently Asked Questions

What is Trikafta?

Trikafta is a medication that treats the underlying cause of cystic fibrosis and makes the condition more manageable, though it is not a cure.

How did Kirsty Parsons gain access to Trikafta?

Parsons initially gained access to Trikafta through a drug trial with Vertex in 2018 while living in England, and continued access upon returning to New Zealand in 2021. It became publicly funded through Pharmac in April 2023.

What was Kirsty Parsons’ connection to Ironman New Zealand as a child?

Cystic Fibrosis New Zealand was a charity sponsor of Ironman New Zealand when Parsons was younger, and she was mentored by athlete Patrick Bristowe, running alongside him at the finish line.

What does it mean to witness individuals overcome significant health challenges and pursue extraordinary goals?